AXSM — Axsome Therapeutics Income Statement
0.000.00%
- $5.18bn
- $5.05bn
- $385.69m
Annual income statement for Axsome Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 50 | 271 | 386 |
Cost of Revenue | |||||
Gross Profit | — | — | 44.8 | 245 | 352 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 100 | 125 | 230 | 502 | 666 |
Operating Profit | -100 | -125 | -180 | -232 | -281 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -103 | -130 | -187 | -238 | -287 |
Provision for Income Taxes | |||||
Net Income After Taxes | -103 | -130 | -187 | -239 | -287 |
Net Income Before Extraordinary Items | |||||
Net Income | -103 | -130 | -187 | -239 | -287 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -103 | -130 | -187 | -239 | -287 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.73 | -3.47 | -4.59 | -5.27 | -5.99 |